Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence.